The Zheng Research Group is at the forefront of innovation in radiopharmaceutical development, focusing on the diagnosis and treatment assessment of neuropsychiatric and neurodegenerative disorders. Under the leadership of Dr. Chao Zheng, our lab combines groundbreaking research in radiochemistry, and quantitative PET imaging to push the boundaries of brain imaging science.

Our work centers on:

1. Discovery of Cutting-Edge Radiopharmaceuticals – We develop state-of-the-art PET radioligands, utilizing advanced Carbon-11 and Fluorine-18 labeling methodologies to capture previously inaccessible biochemical and phenotypic changes in the brain.

2. Novel PET Imaging Applications – We pioneer imaging methods that provide unparalleled insights into the living brain, bridging the gap between preclinical studies and clinical applications to improve diagnostic and therapeutic strategies.

As an interdisciplinary lab, we integrate diverse fields including radiochemistry, pharmacology, neuroscience, medicinal chemistry, and quantitative neuroimaging to tackle complex challenges in translational neuroscience. Students and researchers who join our team will gain hands-on experience in radiochemistry, PET neuroimaging, and in vivo studies, all within a cutting-edge preclinical and clinical research environment.